Andere Sprachen Initiator Pharma A/S

Aktien

A2DJNQ

DK0060775872

INIT

Verzögert Nasdaq Stockholm Andere Börsenplätze 15:53:32 13.05.2024			% 5 Tage	% 1. Jan.
9,2 ^SEK	0,00 %		-2,34 %	-0,43 %

10.05.	Initiator Pharma A/S meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
23.02.	Initiator Pharma A/S meldet Ergebnis für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Initiator Pharma Q1 2024 - Focus on sealing a deal	10.05.
INITIATOR PHARMA: Q1 2024 REPORT	10.05.
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	10.05.
Notice to AGM in Initiator Pharma	02.05.
Annual report and Remuneration report 2023 for Initiator Pharma A/S	02.05.
Initiator Pharma's pudafensine preclinical pharmacology results published in the British Journal of Pharmacology	15.04.
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology	12.04.
Initiator Pharma - Q4 2023 – Breathing optimism	23.02.
INITIATOR PHARMA: YEAR END REPORT 2023	23.02.
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23.02.
Initiator Pharma Issues New Shares for Debt Conversion	21.02.
MAC Clinical Research converts its receivable into shares in Initiator Pharma	21.02.
Initiator Pharma A/S - Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021	24.01.
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021	23.01.
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts	08.01.
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	08.01.
Initiator Pharma Q3 - A historical quarter	10.11.
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10.11.
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine	07.11.
Initiator Pharma - Positive Phase IIb results	10.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Initiator Pharma A/S

Aktien

A2DJNQ

DK0060775872

INIT

Andere Sprachen

Filter